华仁药业股份有限公司 简式权益变动报告书 上市公司名称：华仁药业股份有限公司 股票简称：华仁药业 股票代码：300110 股票上市地点：深圳证券交易所 信息披露义务人：红塔创新投资股份有限公司 住所/通讯地址：云南省昆明市五华区昆明高新区海源北路与科新路交叉口海 源高新天地商业广场1幢21层2108号 权益变动性质：股份减少，持股比例降至5%以下 签署日期：2025年9月9日 1 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第15 号——权益变动报告书》及其他相关法律法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第15号——权益变动报告书》的规定，本报 告书已全面披露信息披露义务人在华仁药业股份有限公司中拥有权益的股份变动 情况。截至本报告书签署日，除本报告书披露的持股信息外，信息披露义务人没 有通 ...

Group 1 - Huazhong Securities has been approved to issue subordinate corporate bonds with a total face value of no more than 10 billion yuan [1] - Jinbei Automotive plans to invest 240 million yuan to establish an automotive industry investment fund focusing on electrification, intelligence, and low carbon [1] - Linyang Energy is expected to win a bid for a 244 million yuan metering equipment project from Southern Power Grid [1][2] Group 2 - Renfu Pharmaceutical's subsidiary has received drug registration certificates for two products, including a medication for acute hypotension [3][4] - Nanjing Steel plans to distribute a cash dividend of 0.1186 yuan per share [5][6] - Pairui Co. has signed a strategic cooperation agreement with Xi'an Power Electronics Research Institute to develop power devices [7][8] Group 3 - Haixing Electric is expected to win a bid for a 214 million yuan metering equipment project from Southern Power Grid [9][10] - Kuangda Technology is planning a change in control, leading to a continued suspension of its stock [11][12] - Samsung Medical is expected to win a bid for a 274 million yuan metering equipment project from Southern Power Grid [13][14] Group 4 - Jiukang Bio has obtained a medical device registration certificate for a specific diagnostic kit [15][16] - Hechuan Technology's minority shareholder plans to transfer a 13% stake in a subsidiary [17][18] - DiAo Micro has launched a new eUSB2 repeater product for various electronic applications [19][20] Group 5 - David Medical's electric surgical table registration application has been accepted [21][22] - Hangxin Technology plans to apply for a total of 280 million yuan in bank credit [23][24] - Liyuan Technology's non-independent director has resigned [25][26] Group 6 - Ningbo Construction's subsidiary has won a construction project bid worth 729 million yuan [27][28] - Huaren Pharmaceutical's subsidiary has received approval for a raw material drug [29][30] - Suwen Electric plans to distribute a cash dividend of 1 yuan per 10 shares [31][32] Group 7 - Solar Energy has received 1.692 billion yuan in renewable energy subsidies [33][34] - Wangli Security has obtained a patent for a new lock structure [35][36] - Zhejiang Energy's vice chairman has resigned due to age reasons [37][38] Group 8 - Beilu Pharmaceutical's subsidiary has passed GMP certification in Brazil [39][40] - Zhejiang Communications has a subsidiary that is expected to win a highway project bid [41][42] - Xinzhi Group has received a government subsidy of 11.1978 million yuan [43][44] Group 9 - Dong'an Power's engine sales in August increased by 3.44% year-on-year [45][46] - Baiyun Mountain's subsidiary has passed the consistency evaluation for two generic drugs [47][48] - Yipin Hong's subsidiary has received a drug registration certificate for a specific injection [49][50] Group 10 - Far East Holdings' subsidiary has won multiple contracts totaling 1.689 billion yuan [51][52] - Good Housekeeping's shareholder plans to reduce holdings by up to 3.5 million shares [53][54] - Guanghong Technology's shareholders have set a transfer price of 23.33 yuan per share [55][56] Group 11 - Keli Sensor plans to acquire 45% of Huahong Technology's shares for 122 million yuan [57][58] - Jianmin Group's furosemide oral solution has been approved for market launch [59][60] - Jinghua Laser's directors plan to reduce their holdings by up to 143,420 shares [61][62] Group 12 - Zhuyue Group is planning a share transfer that will change its controlling shareholder [63][64] - Terid has pre-bid for two projects totaling approximately 698 million yuan [65][66] - Zhonghuan Hailu is planning a change in control, leading to a continued suspension of its stock and convertible bonds [67][68] Group 13 - Great Wall Motors reported August sales of 115,600 vehicles, a year-on-year increase of 22.33% [69][70] - Guizhou Tire's controlling shareholder has committed not to reduce holdings for 12 months [71][72] - San Da Membrane's shareholder plans to reduce holdings by up to 1% of the company's shares [73][74] Group 14 - Chint Electric has decided to terminate the spin-off of its subsidiary for listing [75][76] - Jusaylong's shareholder plans to reduce holdings by up to 1% of the company's shares [77][78]

Group 1 - The core point of the article is that Huaren Pharmaceutical announced the approval of its subsidiary Anhui Hengxing Pharmaceutical's application for "Isoproterenol Hydrochloride" as a chemical raw material drug by the National Medical Products Administration [1] Group 2 - The approval signifies a significant milestone for the company, potentially enhancing its product portfolio and market competitiveness [1]

Core Viewpoint - Huaren Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of Isoproterenol Hydrochloride, indicating a significant advancement in its product portfolio and potential market opportunities [1] Group 1: Company Developments - Huaren Pharmaceutical's wholly-owned subsidiary, Anhui Hengxing Pharmaceutical Co., Ltd., has been granted the approval for Isoproterenol Hydrochloride, a non-selective β-adrenergic agonist [1] - The approval notification number for the marketing application is 2025YS00767, highlighting the regulatory progress made by the company [1] Group 2: Product Information - Isoproterenol Hydrochloride is known for its strong positive inotropic and chronotropic effects, as well as its bronchodilator properties, making it clinically relevant for treating conditions such as cardiogenic or septic shock, complete atrioventricular block, cardiac arrest, and acute bronchial asthma attacks [1]

Core Viewpoint - Huanren Pharmaceutical's wholly-owned subsidiary, Anhui Hengxing Pharmaceutical, has received approval from the National Medical Products Administration for the production and sale of "Isoproterenol Hydrochloride" in the domestic market [1] Group 1 - The approval includes the issuance of a "Chemical Raw Material Drug Listing Application Approval Notice" [1] - The raw material drug has met the relevant technical standards for raw material drug review in the country [1] - This development allows the company to expand its product offerings in the domestic market [1]

Core Viewpoint - Hainan Pharmaceutical's subsidiary, Anhui Hengxing Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of "Isoproterenol Hydrochloride" [1] Company Summary - The approval of Isoproterenol Hydrochloride, a non-selective β-adrenergic agonist, will enhance the company's active pharmaceutical ingredient (API) product line [1] - This product is primarily used for treating cardiogenic or infectious shock, complete atrioventricular block, cardiac arrest, and acute bronchial asthma attacks [1] - The addition of this product is expected to improve the company's market competitiveness [1]

Core Viewpoint - Huanren Pharmaceutical's subsidiary, Anhui Hengxing Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of "Isoproterenol Hydrochloride" [1] Group 1: Company Developments - The approval pertains to Isoproterenol Hydrochloride, a non-selective β-adrenergic agonist that strongly stimulates both β1 and β2 receptors [1] - Isoproterenol Hydrochloride is clinically used for treating conditions such as cardiogenic or infectious shock, complete atrioventricular block, cardiac arrest, and acute bronchial asthma attacks [1]

Core Viewpoint - Huaren Pharmaceutical's subsidiary, Anhui Hengxing Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of Isoproterenol Hydrochloride, a non-selective β-adrenergic agonist used in various clinical treatments [1] Group 1 - The approved drug, Isoproterenol Hydrochloride, is known for its strong positive inotropic and chronotropic effects, as well as its bronchodilator properties [1] - Clinical applications of Isoproterenol Hydrochloride include treatment for cardiogenic or septic shock, complete atrioventricular block, cardiac arrest, and acute bronchial asthma attacks [1]

Core Viewpoint - Huaren Pharmaceutical's subsidiary, Anhui Hengxing Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of Isoproterenol Hydrochloride, indicating a significant advancement in the company's product portfolio and potential market opportunities [1]. Group 1 - The approved drug, Isoproterenol Hydrochloride, is a non-selective β-adrenergic agonist that strongly stimulates both β1 and β2 receptors, showcasing powerful positive inotropic, positive chronotropic, and bronchodilator effects [1]. - The clinical applications of Isoproterenol Hydrochloride primarily include treatment for cardiogenic or septic shock, complete atrioventricular block, cardiac arrest, and acute bronchial asthma attacks [1].

证券代码：300110 证券简称：华仁药业 公告编号：2025-059 华仁药业股份有限公司 关于全资子公司盐酸异丙肾上腺素原料药获得上市申请 批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司安徽恒星制药 有限公司（以下简称"安徽恒星制药"）收到国家药品监督管理局核准签发的"盐 酸异丙肾上腺素"《化学原料药上市申请批准通知书》（通知书编号： 2025YS00767）。现将相关情况公告如下： 一、原料药登记信息 1．通用名称：盐酸异丙肾上腺素 2．英文名/拉丁名：Isoprenaline Hydrochloride 3．化学原料药注册标准编号：YBY68912025 4．包装规格：1kg/桶 5．申请事项：境内生产化学原料药上市申请 6．审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执 行。 7．生产企业 名称：安徽恒星制药有限公司 地址：合肥市包河工业区纬五路 15 号 二、药品的其他情况 盐酸异丙肾上 ...